Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for reduction of myocardial injury in coronary artery disease with angina
IRCT20231015059731N1Phase 3Completed
- Sponsor
- Lorestan University of Medical Sciences
- Start
- Oct 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of colchicine in coronary arteriosclerosis, angina pectoris and Myocardial injury, sponsored by Lorestan University of Medical Sciences. Started Oct 2023; status: completed.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosisangina pectorisMyocardial injury
Beyond the preview
Go deeper on IRCT20231015059731N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231015059731N1.